Zhejiang Huahai Pharmaceutical

What they make

1 input Zhejiang Huahai Pharmaceutical supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

1 facility

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Incident2018

  In July 2018, the FDA and European Medicines Agency discovered that valsartan API manufactured by Zhejiang Huahai Pharmaceutical (Cangnan, Wenzhou, China) — a blood pressure medication used by millions of patients globally — was contaminated with NDMA (N-nitrosodimethylamine), a probable human carcinogen classified by IARC as Group 2A. The contamination was caused by a 2012 manufacturing process change in which a sodium nitrite quench step was combined with a solvent (dimethylformamide) under conditions that generated NDMA as an undetected byproduct. The resulting recall affected hundreds of valsartan-containing products across the US, EU, and other markets — one of the largest pharmaceutical recalls in history. Patients who had been taking potentially contaminated valsartan for up to 6 years received risk notifications. Zhejiang Huahai's valsartan supplied ~25% of US generic valsartan demand. The incident demonstrated that FDA's oversight of foreign API manufacturing was structurally inadequate: the process change that created NDMA occurred in 2012; contaminated API was shipped globally for 6 years before detection by the European Directorate for the Quality of Medicines (EDQM). A manufacturing process change at a Chinese factory in Wenzhou caused a multi-year carcinogen exposure for hypertension patients across North America and Europe.

  U.S. Food and Drug Administration ↗

• Origin2018

  Zhejiang Huahai Pharmaceutical was founded in 1989 in Linhai, Zhejiang Province as China began opening its pharmaceutical industry to export. The company specialized in angiotensin receptor blocker (ARB) APIs — cardiovascular drugs that were coming off patent in Western markets during the 1990s and 2000s. Western generic manufacturers, seeking lower-cost API supply, increasingly outsourced synthesis to Chinese producers including Zhejiang Huahai as FDA approved their facilities for US market supply. By the mid-2000s, Zhejiang Huahai held approximately 40% of the global valsartan API market. In 2012, without notifying regulatory authorities or customers, Zhejiang Huahai changed the synthesis process for valsartan — switching to a tetrohydrofuran (THF) solvent recovery system that generated NDMA (N-nitrosodimethylamine, a probable carcinogen) as a reaction byproduct. This was not discovered until 2018, meaning patients globally had consumed NDMA-contaminated valsartan for 6 years. The FDA valsartan recall was triggered not by internal quality monitoring but by a European generic manufacturer testing API from a different Chinese supplier — demonstrating that the supply chain lacked systematic carcinogen screening.

  US Food and Drug Administration ↗

• Chokepoint2018

  Zhejiang Huahai Pharmaceutical's Cangnan API facility received an FDA warning letter in 2018 after NDMA carcinogen contamination was found in its valsartan API, triggering a global recall affecting millions of patients; the same facility supplies psychiatric APIs, illustrating systemic quality risks embedded in Chinese API concentration

  FDA ↗